Search

Displaying results 3511 - 3520 of 7604 in total
  1. Drug

    MF101

    go.drugbank.com/drugs/DB05052
    Investigational

    MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation

  2. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  3. Drug

    MK-4541

    go.drugbank.com/drugs/DB17016
    Experimental

    MK-4541 is a 4-azasteroid and a selective androgen receptor modulator (SARM). MK-4541 acts as a dual selective SARM and is both a potent androgen receptor antagonist and a 5α-reductase inhibitor.

    Synonyms: 2,2,2-trifluoroethyl N-[(1S,3aS,3bS,5aR,9aR,9bS,11aS)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,9b,10,11-decahydro-1H-indeno[5,4-f]quinolin-1-yl]carbamate
  4. Drug

    MK-5108

    go.drugbank.com/drugs/DB12556
    Investigational

    MK-5108 has been used in trials studying the treatment of Cancer, Neoplasms, Tumors.

  5. Drug

    MK-1496

    go.drugbank.com/drugs/DB12763
    Investigational

    MK-1496 has been used in trials studying the treatment of Neoplasms and Malignant.

  6. Drug

    Equine Botulinum Neurotoxin A Immune FAB2

    go.drugbank.com/drugs/DB13900
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.

  7. Drug

    TG100-115

    go.drugbank.com/drugs/DB05552
    Investigational

    An NSAID that inhibits PI-3K gamma and delta.

  8. Drug

    Tengonermin

    go.drugbank.com/drugs/DB16689
    Investigational

    [L33050] This drug works by modifying the tumor microenvironment and increasing intratumoral chemotherapy penetration and T-cell infiltration. … [A233270] Literature demonstrates that NGR-peptides bind to a CD13 isoform, of which expression is restricted to tumor vasculature cells.

  9. Drug

    Equine Botulinum Neurotoxin F Immune FAB2

    go.drugbank.com/drugs/DB13901
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.

  10. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination